Scienmag
SEPTEMBER 27, 2020
New study based on the early versus late intervention trial with estradiol data confirms benefit of hormone therapy in reducing multiple biomarkers of inflammation CLEVELAND, Ohio (September 28, 2020)–As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health (..)
Medical Xpress
MARCH 6, 2023
The negative mental and physical effects of withholding gender-affirming hormone therapy (GAHT) from transgender people may outweigh the risk of GAHT-associated venous thromboembolism (VTE), underscoring the need for a thorough upfront discussion by healthcare provider and patient, according to a study led by investigators from Massachusetts General (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
APRIL 19, 2021
Hypertension Journal report DALLAS, April 19, 2021 — Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in Hypertension, an American Heart Association journal.
Scienmag
SEPTEMBER 27, 2020
Yale physician to discuss the most promising developments in estrogen therapy, including new fetal estrogens, during the 2020 NAMS Virtual Annual Meeting Pre-Meeting Symposium CLEVELAND, Ohio (September 28, 2020)–Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes.
Scienmag
AUGUST 11, 2020
New study identifies frequency of hormone therapy use and predictors of its use in women who underwent preventive oophorectomy as a result of carrying the BRCA gene CLEVELAND, Ohio (August 12, 2020)–Removal of the ovaries before natural menopause (surgical menopause) often exacerbates menopause symptoms and places women at increased risk for (..)
Scienmag
APRIL 26, 2021
American Heart Association Scientific Statement DALLAS, April 26, 2021 — The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur, according to a new American Heart Association (..)
Drug Discovery World
APRIL 5, 2024
Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). The preclinical data for COR-1167 is very promising and we are excited to determine its therapeutic potential in patients.”
Expert insights. Personalized for you.
46 
Let's personalize your content